Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Kendelle Joan Murphy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3234-3812; OpenAlex author ID A5079283470. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 13

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  3. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  4. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  5. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  6. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy. Co-author DOI 10.1042/bst20220162↗
  7. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  8. Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Co-author DOI 10.3390/cancers13143481↗
  9. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-019-1091-0↗
  10. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  11. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  12. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. First author DOI 10.1053/j.gastro.2017.11.280↗
  13. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul Timpson · 8 shared papers, 2018–2026 · strength 0.94
  2. David Herrmann · 4 shared papers, 2018–2022 · strength 0.49
  3. Jennifer P. Morton · 5 shared papers, 2018–2026 · strength 0.49
  4. Brooke Pereira · 3 shared papers, 2021–2022 · strength 0.44
  5. Amber L. Johns · 4 shared papers, 2018–2026 · strength 0.42
  6. Marina Pajic · 5 shared papers, 2018–2021 · strength 0.37
  7. Anthony James Gill · 3 shared papers, 2018–2026 · strength 0.34
  8. Claire Vennin · 4 shared papers, 2018–2021 · strength 0.29
  9. Cecilia R. Chambers · 2 shared papers, 2021 · strength 0.25
  10. Thomas R. Cox · 3 shared papers, 2018–2021 · strength 0.23
  11. Ashleigh Parkin · 3 shared papers, 2018–2021 · strength 0.22
  12. Angela S. Y. Chou · 3 shared papers, 2018–2021 · strength 0.22
  13. David Goldstein · 1 shared paper, 2026 · strength 0.21
  14. Val Gebski · 1 shared paper, 2026 · strength 0.21
  15. Joshua A. McCarroll · 1 shared paper, 2026 · strength 0.21
  16. Mert Erkan · 1 shared paper, 2026 · strength 0.21
  17. Koroush Shahsavar Haghighi · 1 shared paper, 2026 · strength 0.21
  18. Phoebe A. Phillips · 1 shared paper, 2026 · strength 0.21
  19. George Sharbeen · 1 shared paper, 2026 · strength 0.21
  20. John Kokkinos · 1 shared paper, 2026 · strength 0.21
  21. Minoti Vivek Apte · 1 shared paper, 2026 · strength 0.21
  22. Owen James Sansom · 3 shared papers, 2018–2021 · strength 0.19
  23. Australian Pancreatic Cancer Genome Initiative (APGI) · 2 shared papers, 2020–2021 · strength 0.16
  24. Yingxiao Wang · 2 shared papers, 2018–2021 · strength 0.14
  25. Max Nobis · 2 shared papers, 2018–2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.